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The HN-1 module was previously reported to ensure eﬃcient targeting of head and neck squamous cell carcinoma (HNSCC).
Aim of this work was to indentify the target of HN-1. Targeting of HN-1 peptide was compared in normal epithelial cells (BEAS-
2B) and in HNSCC tumor cells (SCC-25 and Detroit 562). Experimental, cell culture, cell polarity, and adhesion conditions
were tested; structure models of peptides were created. Indeed, HN-1 was able to target HNSCC tumor cells in the previously
published conditions. The targeting eﬃciency of immortalized normal epithelial cells was signiﬁcantly lower. Nevertheless, in
other experimental conditions the binding was less eﬃcient and not speciﬁc. A scrambled sequence of HN-1, with altered order
of amino acids showed even better targeting eﬃciency than HN-1. HN-1 was only uptaken in adherent cells, not in suspension.
In conclusion, HN-1-peptide-targeting is not based on sequence speciﬁcity, but more on electrostatic interactions with the cell
surface of the tumor cells.
1.Introduction
Promising newtherapies forHNSCCrequire tumor-targeted
approaches that aﬀord tumor speciﬁcity and limited toxicity.
Identiﬁcation of tumor-speciﬁc peptides for targeted drug
delivery into solid tumors rises an opportunity for tumor-
speciﬁc delivery of therapeutic payloads [1].
The development of diverse peptide libraries over the
past decade has ushered in the opportunity to identify
small peptides that may not be as limited as the larger
antibody predecessors [1]. Recently, several research groups
developedpeptide-based therapy ideas as options for tumor-
speciﬁc targeting. Small peptides were often represented
as tumor-speciﬁc targeting aids. As an example, Hsiao et
al. developed a so-called Phage/peptide-29, which prefer-
entially bound to integrin αvβ6 rather than to other αv-
associated integrins [2]. Peptide-29 signiﬁcantly inhibited
the proliferation of oral squamous cell carcinoma cells in
3Dcellcultures.Onhumanpathologicalsections,peptide-29
targeted oral cancer cells in a αvβ6-dependent manner [2].
Nothelfer et al. also discuss an HNSCC aﬃne peptide
(HBP-1) derived from a phage display library [3]. Authors
performed peptide immunohistochemistry of HNSCCtissue
sections and exhibited tumor staining by HBP-1, whereas
normal tissue remained negative. Sequence mutation and
competition experiments revealed that the intrinsic RGD
motif in combination with the intrinsic LXXL motif was
responsible for the binding ability of HBP1. The RGDLXXL
sequence within this peptide is known and indicates that
binding occurs via the αvβ6 integrin, which is exactly the
same conclusion as the one of Hsiao et al. [2, 3].
In fact, peptide-targeting of HNSCC has already been
publishedovertenyearsago,byHongandClayman[1].They
have also used phage-display and found a novel peptide,
HN-1, which internalized speciﬁcally to HNSCC cells. In
2009 Bao et al. combined the HN-1 peptide of Hong and
Clayman [1] with a proteinkinase Cq (PKCq) inhibitory
module, which has functioned as a speciﬁc PKCq inhibitor
[4].TheeﬃciencyandselectivityofHN1-PKCqcombination
was tested in HNSCC cells in vitro compared with oral2 ISRN Oncology
epithelial cells. In contrast to a minimal labeling of normal
epithelial cells (1.9%), the HN1-PKCq combination labeled
up to 86.5% of the HNSCC cells [4]. This second study
corroboratedtheﬁndingsofHongandClayman[1]andcon-
ﬁrmed a HNSCC-speciﬁcity of HN-1, and its combination
with PKCq-targeting reached eﬀectiveantitumor actions [4].
Being HN-1 the only targeting peptide whose HNSCC-
speciﬁcity has been independently proven by more research
groups [1, 4], it was also chosen by us for a basis of a
novel, targeted nanoparticle tumor therapy. The concept is
to use selective targeting ligands on the surface of complex
nanoparticles [5], whose binding and internalization speci-
ﬁcity assures the selective delivery of cytostatic payload to
tumor cells. In this study, in order to ﬁt with our strict
requirements for tumor selective targeting, the following
aspects of HN-1 binding and internalization were investi-
gated:
(i) sequence speciﬁcity of HN-1-mediated HNSCC-tar-
geting,
(ii) reproducibility of HN-1-mediated HNSCC-target-
ing,
(iii) comparison of the targeting of immortalized epithe-
lial cells (BEAS-2B), primary lingual HNSCC cells
(SCC-25), and metastatic pharyngeal HNSCC cells,
(iv) in which extent the localization of the original tumor
o ft h ec e l ll i n ea ﬀects the targeting?
(v) inﬂuenceofexperimental conditionsonthetargeting
by HN-1, usage of physiological conditions,
(vi) identiﬁcation of the target.
Our ﬁndings demonstrate that the published results of
Hong and Clayman [1]a n dB a oe ta l .[ 4] are reproducible
only in the same experimental conditions; HN-1 does not
show an amino acid sequence-speciﬁc targeting, butit might
bestructure speciﬁc; HN-1might bind tomultipletargetson
a surface of a polarized cell, but has no targeting function
to suspended cells. HN-1 targets primary and metastatic
tumor-derived cell lines and targets only at a very low
eﬃciency immortalized, but not transformed cells.
2.Materialsand Methods
2.1. Cultured Cells. In this study, BEAS-2B immortalized
bronchial epithelial cells [6], SCC-25 lingual squamous cell
carcinoma cells [7], and Detroit 562 metastatic pharyngeal
squamous cell carcinoma cells were used [8]. All of these cell
lines were of commercial origin, and their culture conditions
are summarized in Table 1.
2.2. Peptides. In this study, the following peptides were used:
HN-1 published by Hong and Clayman (2000) [1], a scram-
bled version of HN-1 was designed by Dr. Fritz Andreae
(Pichem, Graz Austria), and another, with HN-1 not-
related peptide sequence was also used and was labeled
as “irrelevant”. The peptide sequences are summarized in
Table 2.PeptidesweresynthesizedbyPichem(Graz,Austria).
2.3. Structure and Folding Analysis of the Peptides. The pep-
tide secondary structures and folding were predicted by PEP-
Fold, an online resource for de novo peptide structure pre-
diction [9]. PEP-Fold provided pdb (protein data bank) ﬁles
with representation of macromolecular structure. Pdb ﬁles
were visualized by a Deepview/Swiss-Pdbviewer [10–14].
Protein-protein interaction sites were predicted as described
before [15].
2.4. Peptide-Binding in Cell Suspension. Cells were counted,
and 1 × 106 cells were incubated with 1μM peptides in PBS
or in complete medium containing 10% fetal bovine serum
for 10–30 minutes at room temperature [3], followed by
centrifugation at 290g, 4◦C. Cells were washed two times
with PBS and were then taken into Isoﬂow Sneath (Coulter,
Vienna, Austria) for ﬂow cytometry analysis.
2.5. Incubation of Cells with Peptides. In Petri dishes, 0.5–
1 × 106 cells were plated and they were cultured routinely
for 48 hours. Peptides were given to the cells after this time
at concentrations of 1–3μM, in 0.3–4% serum-containing
medium, and in 4% BSA-containing medium for 1–24
hours. After incubation the conditioned medium was either
collected or discarded. Cells were washed twice with PBS
and were removed from the culture surface with EDTA
solution or with trypsin (PAA, Linz, Austria). The resulting
cell suspension was given back to the collected conditioned
medium, or it was collected separately from the conditioned
medium in centrifuge tubes. The cell suspensions were
centrifuged at 290g, 4◦C for 5 minutes, and the cell pellets
were collected in 1mL isoﬂow sneath.
2.6. Flow Cytometry. Cell suspensions were examined in
a Coulter EPICS XL-MCL (Vienna, Austria) by using the
EXPO 32 software. Baseline conditions were measured by
cells incubated without peptides. Increase of ﬂuorescence
signal related to the control baseline was measured by
detecting either extra peaks in the histogram of the FL-1-
channel or by shifting the histogram to the right compared
to the control baseline [4]. Also peptide solutions were
tested in the ﬂow cytometer, and they did not show signals
comparable with cell signals.
2.7. Peptide-Coating Experiments. In order to investigate if
HN-1 or other peptides might attach cells from suspension,
glass cover slips were coated with peptides or with poly-D-
Lysine (as a positive control) at 50μg/mL, as it was published
before [16, 17]. After coating and washing steps, the cover
slips were loaded with 1% BSA/medium at 37◦C for 1 hour
[18]. The cells were plated at 2 × 104/mL in serum-free
medium, for 1 hour at 37◦C[ 18], followed by removal
of medium with not adherent cells, 3 washes with serum-
free medium, addition of serum-containing medium and
culturing for 48 hours at 37◦C .A f t e rc u l t u r e ,t h ec e l l sw e r e
ﬁxed in 4% PFA in PBS for 20 minutes, washed with PBS,
stained routinely with Hematoxyllin, and covered with glass
slides in glycerin-gelatin. The slides were visualized in an
Olympus BX50 (Tokyo, Japan) microscope.ISRN Oncology 3
Table 1: Cultured cells and culture conditions.
Name Histology Localization Source Culture medium Purchased from
BEAS-2B Epithelial cells Bronchial Not transformed
immortalized epithelial RPMI 1640 ECACC: European Collection Agency of
Cell Cultures (Salisbury, UK),
SCC-25 Squamous cell
carcinoma Lingual Primary tumor
Ham’s F12 +
Dulbecco’s MEM
(at 1:1)
D S M Z :G e r m a nC o l l e c t i o no f
Microorganisms and cell cultures
(Braunschweig, Germany)
Detroit-562 Squamous cell
carcinoma Pharyngeal Metastatic
Ham’s F12 +
Dulbecco’s MEM
(at 1:1)
CLS: Cell Lines Service (Heidelberg,
Deutschland)
All the cell lines were used within 6 months of purchase, and the identity was declared by the deliverers.
Table 2: Used peptides. The polar or charged amino acids were labeled in bold. Peptides were FITC-labeled at the NH2-terminal.
Peptide Designed by MWg /mol Sequence1-letter-code Sequence3-letter-code
HN-1 (Dr. Hong et al.) 1320,5 TSPLNIHNGQKL Thr-Ser-Pro-Leu-Asn-Ile-His-Asn-Gly-Gln-Lys-Leu
HN-1-scr Dr. F. Andreae,
Graz, ¨ Osterreich 1320,5 LNKQTHGLIPNS Leu-Asn-Lys-Gln-Thr-His-Gly-Leu-Ile-Pro-Asn-Ser
Irrelevant Storkbio, Tallin,
Estonia 1550,7 GGGRHAYHMHPHHG Gly-Gly-Gly-Arg-His-Ala-Tyr-His-Met-His-Pro-
His-His-Gly
2.8. Fluorescence Microscopy. SCC-25 cells were plated at
104/0.5mL in chambered slides and grown in culture
mediumfor48hours,followedbymediumreplacementwith
0.3% serum-containing medium and incubation with HN-
1o rs c r - H N 1a t1μM for 6 hours. The peptide-containing
medium was removed and discarded, followed by washes
with PBS, ﬁxation in 4% Paraformaldehyde (PFA) for 20
minutes, DAPI-staining, and visualization in a ﬂuorescent
microscopy (Axio-ImageM, Zeiss, Jena, Germany) at 200x
original magniﬁcation.
2.9. Statistical Data Analysis. Statistical signiﬁcance of the
diﬀerence between data sets was determined by one-way
analysis of variance.
3.Results
3.1. Reaction of HN-1 Compared to Other Peptides with Cells
in Published Conditions. At the ﬁrst step, we reproduced
the experimental conditions of Bao et al. (2009) [4]a n d
incubated the peptides at 3μM concentration with the cells
for 24 hours. In these conditions, in average 56.15% of SCC-
25 cells, 55.2% of Detroit 562 cells, and 12.92% of BEAS-
2B cells showed FITC-positivity after incubation with HN-1;
69.2% ofSCC-25cells, 47.9% ofDetroit 562 cells, and 5.45%
of BEAS-2B cells showed FITC-positivity after incubation
with scr-HN-1; 31.05% of SCC-25 cells, 31.6% of Detroit
562 cells, and 3.2% of BEAS-2B cells showed FITC-positivity
after incubation with the “irrelevant peptide” (Figure 1). In
general, the primary tumor- and the metastasis-originated
cells showed higher peptide-related gain of ﬂuorescence
than the immortalized, normal epithelial BEAS-2B cells
(Figure 1). Interestingly, this higher peptide-related gain of
ﬂuorescence was found by any peptide sequence. HN-1
reacted with SCC-25 and with Detroit 562 cells at the same
level (56.15–69.2% positive cells in average, P>. 05, One-
wayANOVA),butscr-HN-1signiﬁcantlyhigherreacted with
SCC-25 cells than with Detroit 562 cells (P = .005, One-
way ANOVA) (Figure 1).
3.2. Reaction of HN-1 Compared to Other Peptides with Cells
during Shorter Incubation Time. 3μMo fH N - 1p e p t i d e
represents ca. 4mg/L peptide concentration, 24 hours incu-
bation time is relatively suboptimal for therapeutic use, and
24 hours keeping the peptide intact in blood circulation
conditions is unreliable. This might indicate a requirement
of administration of an even higher peptide concentration.
Seeing our concept of a targeting ligand for delivering a
payload, lower peptide concentrations and shorter incu-
bation times were foreseen. In this regard, SCC-25 cells
were treated with HN-1, scr-HN1, and with the “irrelevant”
peptide at 1μM peptides by 1 million cells for 1h [3, 19]. In
the ﬁrst set, the peptide-containing medium was discarded
after the 1h incubation; the cells were washed three times
with PBS and then removed from the culture surface by
trypsinization. 2.3% of the SCC-25 cells showed ﬂuorescein
(FITC/FAM) reaction increased above the baseline, after 1h
incubation with HN-1, and 2.9% after 1-h incubation with
scr-HN-1. By increasing the concentration of the peptides
to 3μM, 12.3% of the cells showed ﬂuorescein (FITC/FAM)
reaction increased above the baseline after incubation with
HN-1, and 19.1% after incubation with scr-HN-1, and 2.5%
after incubation with the “irrelevant peptide”. These results
indicate that the peptide concentration cannot be decreased,
and 1h incubation delivers drastically lower interaction with
t u m o ro rn o r m a lc e l l s .
In the second set, the peptide-containing medium was
not discarded after the incubation, but collected; the cells
were washed three times with PBS and then removed from
the culture surface by trypsinization. Subsequently, the cells
were given back to the corresponding peptide-conditioned
medium; they were centrifuge-separated from the peptide
solution; the pellet was dissolved and FACS-analyzed. By
using 1μMp e p t i d ef o r1 0 6 plated cells, 84.7% of the cells4 ISRN Oncology
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Figure 1: Peptide uptake in SCC-25 (a), Detroit 562 (b), and
BEAS-2B(c)cellsinpublished conditions.Thecellswere plated and
incubated according to Bao et al. [4]. Tumor cells showed higher
peptide interaction than BEAS-2B cells; the binding reaction to
“irrelevant” peptide sequence was much lower than that of HN-1
and of its scrambled sequence. The highest binding was found in
SCC-25 cells for scr-HN-1 peptide.
showed ﬂuorescein (FITC/FAM) reaction increased above
the baseline after incubation with HN-1, 59.1% of the
cells after incubation with scr-HN-1, and 38% of the cells
after incubation with the “irrelevant” peptide. These results
indicate that a double contact of the cells with the peptides
dramatically improves their binding.
If BEAS-2B cells were used, the peptide-containing
medium was not discarded after the incubation, the double
contact of the cells with the peptides was allowed, 9.9% of
the cells showed ﬂuorescein (FITC/FAM) reaction increased
above the baseline after incubation with HN-1, 34.1% of the
cells after incubation with scr-HN-1, and 82.4% of the cells
after incubation with the “irrelevant” peptide.
These results were obtained with 0.3% serum-containing
medium. With 4% serum-containing medium or with 4%
serum albumin-containing medium, all cells were FITC-
positive, indicating the complete binding of the peptide after
the double contact.
3.3. Analysis of Peptide Binding to Cells in Suspension. In pre-
viously described experiments, the giving back of peptide-
containing medium to the cells incubated with the peptides
before in an attached culture seriously increased the peptide
interaction with the cells. This indicated that the cells might
bind the peptides also in suspension, within the time from
their removal from adherent culture, giving back of the
peptide-containing medium, centrifugation, suspension in
isotonic solution, and ﬂow cytometry. This is not more than
30 minutes.
In accordance, we have investigated if the cells in sus-
pension bind the peptides within such a short time. We
incubated 106 SCC-25 cells with 1μM peptides in PBS or in
10% FBS-containing complete medium for 10–60 minutes
at room temperature, mimicking the preparation conditions
of trypsinized cells before ﬂow cytometry. Importantly, the
cells were washed after incubation. We determined the % of
positive events, which showed emerged ﬂuorescence levels
from the baseline in the FL-1 channel by FACS. After 10
minutes, the controls showed 1.16 ± 0.06%, the incubation
with HN-1 3.3 ± 0.3%, with scr-HN-1 3.5 ± 0.3, and with
“irrelevant” 1.8 ± 0.2% positive events.After 60 minutes, the
controls showed 0.6 ± 0.1%, the incubation with HN-1 2.3
± 0.3%,withscr-HN-1 2.6 ± 0.3,and with “irrelevant”0.5 ±
0.05%positiveevents.Theusageofserumoralbuminduring
the incubation did not improve these results (not shown).
These results showed that the peptides were attached to less
than 5% of the cells in suspension. For peptide-binding, a
preincubation with peptide in attached culture was required.
This means that there is no primary target for peptide-
bindinginsuspendedcells.Anincreasedincubationtimehad
no inﬂuence on the results.
The previous results show that more contact of peptide
to the cells improved its binding, but the peptide did not
bind to the desired SCC-25 cells in suspension. This issue
was tested in an alternative approach. We investigated if the
peptides ﬁxed to glass surface are suitable for binding tumor
cells from a cell suspension, that is, if they can suit the
concept of purging of circulating tumor cells of HNSCC.
For this approach, we strictly followed already described
methods [16, 17]. SCC-25 and BEAS-2B cells were given
on the coated surfaces for 1 hour, then the surfaces were
washed, and the cells were grown for two days. The SCC-
25 cells showed relative ineﬃcient growth on glass surface
(Figure 2(a)); nevertheless, this was not improved, if the
glass was coated by HN-1 or scr-HN-1 (Figures 2(b) and
2(c)). As a positive control poly-D-lysine coating was used
(Figure 2(d)),whichprovidedasurfaceofaneﬃcientgrowth
for SCC-25. BEAS-2B cells have grown eﬃciently on glassISRN Oncology 5
Glass
(a)
HN-1
(b)
scr-HN-1
(c)
poly-D-lysine
(d)
Glass
(e)
HN-1
(f)
scr-HN-1
(g)
poly-D-lysine
(h)
Figure 2: Attachment of SCC-25 (a)–(d) and BEAS-2B (e)–(h) cells to glass (a), (e), peptide-coated (b), (c), (f), (g) and poly-D-Lysine-
coated (d), (h) glass surfaces. The cells were plated and incubated as described in Materials and Methods. After culture, the cells were ﬁxed
in 4% PFA in PBS for 20 minutes, washed, stained routinely with hematoxyllin, and covered with glycerin-gelatin. Images were taken at 40x
original magniﬁcation.Bars: 100μm.6 ISRN Oncology
(Figure 2(e)),which hasnot beeninﬂuencedby HN-1orscr-
HN-1(Figures 2(f) and 2(g)); nevertheless, on poly-D-lysine
coating these cells grew also better (Figure 2(h)).
3.4. Intracellular Peptide Analysis. SCC-25 cells were treated
with HN-1 or scr-HN-1 in 0.3% serum-containing medium
for 6 hours; the cells were washed, ﬁxed, and observed
in a ﬂuorescent microscope. Only very few cells showed
internal ﬂuorescein signal after incubation with HN-1; there
were no FITC-positive cells after incubation with scr-HN-1
(Figure 3).
3.5. Structure and Folding Characteristics of the Used Peptides.
By using the PEP-fold resource, we investigated the structure
of the peptides. In the report of Hong and Clayman (2000)
[1], an NQHSKNTLLIGP jumbling peptide was used, which
in contrast to the original HN-1 (Table 2) did not internalize
into squamous cell carcinoma cells. In the original HN-1,
an intermittent sequence of polar and apolar amino acids
was visible (TSPLNIHNGQKL) (the polar amino acids are
labeled in bold). The polar amino acids are in single or
double blocks interrupted by apolar amino acids. Hong
and Clayman created a jumbled sequence [1], where they
collected the polar amino acids together, and the apolar
amino acids to the other side: NQHSKNTLLIGP. The three-
dimensional structure of HN-1 is relative wide, based on the
intermittent sequence of the polar and apolar amino acids
(Figures 4(a) and 4(d)). The jumbled HN-1 (of [1]) is more
compact, the basic amino acids are located in the middle of
the molecule, in the same axis, nearly linearly (Figure 5(c)).
In HN-1, the basic amino acids form an approximately
115◦ angle with each other (Figures 4(a) and 5(a)). In the
jumbled HN-1, the apolar amino acids are located in the
same side of the molecule (Figure 5(c)), while in HN-1 they
are alternated (Figures 4(a) and 5(a)). We have generated
ad i ﬀerent scrambled sequence of HN-1: LNKQTHGLIPNS
(the polar amino acids are labeled in bold). In this case, the
polar and the apolar amino acids were clustered, but they
were relative alternately represented in a polar-apolar-polar
sequence. The three-dimensional structure of this peptide
was also more compact than the original HN-1, the basic
amino acids are perpendicular, and form an approximately
90◦ angle with each other, and the apolar amino acids
are located alternated (Figures 4(b), 4(e), and 5(b)). The
secondary structuremotivesofHN-1andofthejumbledand
scrambled peptides are also diﬀerent.While HN-1 containsa
strand (Figure 4(d)), both mixed sequences contain a helix
(Figures 4(e) and 5(d)). In this study, a totally irrelevant
peptide was also used as a control, called “irrelevant”, built
formcompletelydiﬀerentaminoacids,andshowingdiﬀerent
structures, with some accidental small similarities to HN-1
(Figures 4(c) and 4(f)).
3.6. Amino Acid Sequence Analysis of HN-1. By analyzing
of HN-1 sequence (TSPLNIHNGQKL), the bold labeled
amino acids have been found to be involved in protein-
protein interactions using published analysis tools [15].
In the scr-HN1 peptide (LNKQTHGLIPNS), completely
diﬀerent amino acids were predicted to be involved in
(a)
(b)
(c)
Figure 3: Internal peptide detection in SCC-25 cells after 6 hours.
SCC-25 cells were plated at 104/0.5 mL in chambered slides
and incubated with HN-1 (b) and scr-HN-1 (c) for 6 hours,
followed by washes with PBS, ﬁxation in 4% PFA, DAPI-staining,
and visualization in a ﬂuorescent microscopy at 200x original
magniﬁcation. (a) represents control cells. By the incubation with
scr-HN-1 only very few cells showed intracellular localization,
mainly at site of cell-cell adhesions. Bars: 100 μm.
protein-protein interactions. Taking also these data into
consideration Swiss-prot analysis of HN-1 and scr-HN1
was performed and no shared similar proteins were found.
Based on the binding properties of HN-1 to HNSCC
cells (binding exclusively to adherent culture of polarized
cells), an HN-1 similar protein, hemicentin (ﬁbulin-6), has
been further investigated: TSPLNIHNGQKLi st h eH N -
1 sequence, where the bold labeled amino acids of HN-
1 are identical with hemicentin. We have designed human
Hemicentin primers, performed real-time RT-PCR, and no
expression of hemicentin was found in HNSCC tumor cells
and with HNSCC cells cocultured ﬁbroblasts (not shown).ISRN Oncology 7
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Figure 4: Three-dimensional peptides structure of the studied peptides. Representation of polar, basic, and nonpolar amino acids (a)–(c),
and the secondary structure (d)–(f). The structure was calculated by the PEP-Fold software and visualized by Deepview/Swiss-Pdb-viewer.
In (a)–(c) the polar, basic, and apolar amino acids are visualized in colors, in (d)–(f) the secondary structure elements are visualized. White
color means “coil” in (d)–(f).
4.Discussion
The HN-1 module is a 12-mer peptide, which was reported
to preferentially bind and internalize into HNSCC cell lines
in vitro; moreover, it was shown to be stable in vivo and
able to localize into HNSCC xenograft tumors [1, 4]. Bao
et al. [4]d e m o n s t r a t e dt h ee ﬃciency and selectivity of a
HN1-PKCε combined peptide in HNSCC cells in vitro,8 ISRN Oncology
12.2307 cm
Jumbled-HN-1
of Hong et al.
Coil
Helix
Coil
Helix
Jumbled HN1-secondary
HN1–scr-secondary
Polar
Basic
Non-polar
HN-1
Polar
Basic
Non-polar
(a)
(b)
(c)
Polar
Basic
Non-polar
Scr-HN-1
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(e)
Figure 5: Comparison of HN-1 structure with diﬀerent scrambled peptides. Representation of polar, basic, and nonpolar amino acids
(a)–(c), and the secondary structure (d)–(e). The structure was calculated by the PEP-Fold software and visualized by Deepview/Swiss-
Pdb-viewer. In (a)–(c), the polar, basic, and apolar amino acids are visualized in colors; in (d)–(e) the secondary structure elements are
visualized.
with a series of diﬀerent FITC-labeled peptides (peptides at
3μmol/L, incubated 24–48 hours) followed by ﬂuorescence-
activated cell sorting (FACS) analysis. In normal epithelial
cells, FITC-labeled HN1-PKCε showed only uptake in 1.9%
of the cells. In contrast, FITC-labeled HN1-PKCε treatment
of UMSCC1 and UMSCC36 cells resulted in 82.1% and
86.5% FITC-positive cells, respectively [4]. In our study,
similar high uptake of HN-1 peptide was found in SCC-
25 and Detroit 562 cells, and BEAS-2B showed signiﬁcantly
lower uptake (Figure 1). In this regard, our study conﬁrmed
these published results [1, 4] using other cell lines, which are
commerciallyavailablefromcellbanks.Theseresultssupport
the following conclusions:
(i) HN-1 targets HNSCC tumor cells independently
from that they are originated from primary tumor or
from metastasis;
(ii) the targeting of immortalized normal epithelial cells
is signiﬁcantly lower;
(iii) a scrambled version of HN-1, where the sequence
o r d e ro fa m i n oa c i d si sd i ﬀerent from the original
HN-1, shows the same, not statistically diﬀerent
eﬃciency as HN-1 in the adapted conditions from
Bao et al. [1, 4];
(iv) thetargeting ofHN-1isnotstrictly sequencespeciﬁc;
it might berelated to therelative position angle oftheISRN Oncology 9
positive-charged amino acids and to an intermittent
structure of polar and apolar amino acids;
(v) normal, immortalized epithelial cells have taken any
peptide with a lower eﬃciency.
In our study, we also tested other conditions, like other
incubation times, concentrations, and serum conditions [2,
20]. We found that higher albumin and serum concen-
trations (4% instead of 0.3–1%) lead to increased peptide
binding,andalsotoincreased bindingofunspeciﬁc peptides.
It has been already reported that albumin inﬂuences the
functions of peptides [21]. The peptide binding in short
incubation time was seemingly eﬃcient, (we could detect
up to 100% of the cells showing gain of ﬂuorescence), in
contrast, it was only detectable with a “double contact” to
the peptide, by keeping the peptide-containing medium and
giving it back to the cells after resuspension with trypsin.
PBS-washescouldcompletelyremovepeptidesfromthecells.
In this regard, we did not see strong and speciﬁc peptide
binding on the cell surface within short incubation time,
also washed slidesdid revealvery low internal peptidesignals
within the cells (Figure 3).
Conﬁrming the data of Bao et al., long incubation
time (from 20 hours) and high peptide concentrations are
required for eﬀective binding and uptake. Bao et al. worked
even with 30μMp e p t i d e s[ 4]. Both the time and the con-
centration are suboptimal for further consideration.
In our study, a strict sequence speciﬁcity of HN-1 was
not conﬁrmed in SCC-25 and Detroit 562 HNSCC cells.
It seemed like that a relative position of positive-charged
amino acids and an alternating position of polar and apolar
amino acids are required for binding (Figures 4 and 5).
Further outcome of our study is that, the target of HN-1
is not clear. Both the analysis of sequence speciﬁcity and
the secondary structure analysis aimed to get nearer to the
identiﬁcation of the target. The sequence speciﬁcity could
not be credited, while the used scrambled HN-1-sequence
showing completely diﬀerentsequence similarities than HN-
1 showed similarly good uptake results as HN-1. Also the
secondary structure identiﬁcation could not bring us nearer
to the identiﬁcation of the target. The determination of
protein-protein interactive amino acids also ruled out a
deﬁned interactive motive of HN-1, conﬁrming the data
of Hong that HN-1 probably does not bind through its
NGQ-motive [1]. Nevertheless, some issues could have been
claimed. The target, based on the sequence analysis and the
experimental data, is involved in cell-matrix interaction or
in cell-cell contact. It is required for the targeting that the
cellsgrowinnodulesand notseparately distributedasBEAS-
2B. Also the peptide uptake did not work in suspension,
while it either requires the polar structure of the cells or the
cell-cell contacts. HN-1 and scr-HN1 could not improve the
attachment of the cells to glass surface; they do not interact
with suspendedcells. Atthesame time, it probablyuses some
attachment, adhesion, and growth properties of HNSCC,
which supports its HNSCC-speciﬁcity.
T h e r ea r et w oc r i t i c a lp o i n t si nt h er e s u l t so ft h i ss t u d y .
The binding of HN-1 to normal (immortalized) epithelial
cells is low, but it is not 0. It is also important to mention
that those cells had lower binding to any peptide sequence in
general (Figure 1). In the report of Hong and Clayman [1]
cell lines from primary tumors of the ﬂoor of the mouth
and the larynx were used. Bao et al. used malignant oral
squamous cell carcinoma cells; we have used squamous
cell carcinoma cells originated from primary lingual SCC,
and metastatic SCC cells from the pharynx. This is the
ﬁrst report showing the eﬃciency of HN-1 in metastatic
cells. The used cell lines represent diﬀerently staged original
tumors and diﬀerent histological locations. Taking also into
consideration that squamous cell carcinoma of head and
neck is usually a heterogeneous tumor, it is hard to expect
that a 12-mer peptide eﬀectively and sequence-speciﬁcally
targets all HNSCC tumors. The in vivo xenograft results of
Hong and Clayman [1] can be also explained by an aﬃnity
of the peptide to human tissue within the mouse; there is no
direct proof for tumor speciﬁcity by those experiments.
Targeted therapies represent an attractive approach to
circumvent nonspeciﬁc cytotoxicity of conventional anti-
cancer treatments [3]. Peptides do provide the advantage
of small molecules, an advantage that enables them to
serve as promising carrier molecules for drug targeting
or as tracer molecules for tumor imaging. The technique
for designing HNSCC-targeting peptides was comparable
in several reports, a 12-amino-acid peptide phage display
system [1, 3], but the cell lines used were always diﬀerent, as
also the amino acid sequence and secondary structure of the
described peptides. Both studies, Hong and Clayman, 2000
and Nothelfer et al., 2009 [1, 3] generalize the ﬁndings based
on in vivo data and state that the found peptide is HNSCC
speciﬁc. Bao et al. used diﬀerent cell lines and conﬁrmed
the ﬁndings of Hong and Clayman [4]. We could also see
eﬀective uptake of HN-1 in commercially available HNSCC
cell lines.
The main problem of HN-1 is that the target is not an
identiﬁed receptor sequence, but a cell surface negative
charged molecule, most probably a glycosaminoglycan-
protein-complex. Fromthe results, it seems that the presence
ofthetargetisdependentontheconditions.Interestingly,the
change of amino acid sequence did not abolish the function
of HN-1.
The sequence similarities of HN-1 to hemicentin were
interesting, but hemicentin expression was not conﬁrmed
in HNSCC cells. Hemicentins are recently described extra-
cellular matrix (ECM) proteins with a single ortholog in
C. elegans that assembles into discrete tracks constricting
broad regions of epithelial cell contact into adhesive and
ﬂexible line-shaped junctions. The pericellular localization
of vertebrate hemicentins on epithelia and other cell surfaces
suggests that vertebrate hemicentins, like their nematode
counterpart, are secreted ECM proteins likely to have a role
i nt h ea r c h i t e c t u r eo fa d h e s i v ea n dﬂ e x i b l ec e l lj u n c t i o n s ,
particularly in tissues subject to signiﬁcant amounts of
mechanical stress [22]. Taking the original concept of this
study into consideration, HN-1 without clearly deﬁnable
binding and uptake mechanisms is not a valid targeting
ligand for nanoparticles carrying therapeutic payloads. Nev-
ertheless, in combination with other peptides it might be10 ISRN Oncology
still used for intended accumulation of adjuvant agents to
tumor cells.
5.Conclusions
Taken together, the results conﬁrmed that peptide-targeting
of a currently unknown cell surface structure in diﬀerent
HNSCC tumor cells of primary tumor and of metastasis is
possible. The binding of HN-1-peptide is dependent on the
experimental conditions and is not strictly structure speciﬁc.
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